Trials / Recruiting
RecruitingNCT05789043
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma: a Multicenter, Prospective, Randomized Controlled Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | camrelizumab+apatinib+TMZ | camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28 |
| DRUG | camrelizumab+apatinib | camrelizumab 200mg，q2w+apatinib 250mg qd |
| DRUG | camrelizumab | camrelizumab 200mg，q2w |
Timeline
- Start date
- 2023-03-21
- Primary completion
- 2026-08-15
- Completion
- 2027-02-15
- First posted
- 2023-03-29
- Last updated
- 2023-09-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05789043. Inclusion in this directory is not an endorsement.